The Boston Globe

Business

Boston.com

Avastin disappoints against ovarian cancer

Associated Press

  December 29, 2011

Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too. Two studies found it did not improve survival for most of these patients and kept their disease from worsening for only a few months, with more side effects.

Thank you for reading BostonGlobe.com. You have reached the monthly limit for free articles — to continue reading, get unlimited access to BostonGlobe.com now for just 99¢ for 8 weeks.

Unlimited access to BostonGlobe.com includes:

  • The FULL story all day: Enjoy all of the high-quality, in-depth journalism in the print edition of the Boston Globe — plus breaking news that's updated 24/7.
  • A truly reader-friendly format: It's online news that looks and reads just like the newspaper — uncluttered, uninterrupted.
  • Breakthrough technology: The responsive design automatically adapts content so it always reads perfectly on the digital device of your choice.
GET STARTED TODAY

Free access for home delivery subscribers.

Just need to link your home delivery account; one easy step.

Link my home delivery account

BostonGlobe.comSubscriber Log In

Contact us for help